ZA201705628B - Methods and compositions for treating genetic eye diseases - Google Patents
Methods and compositions for treating genetic eye diseasesInfo
- Publication number
- ZA201705628B ZA201705628B ZA2017/05628A ZA201705628A ZA201705628B ZA 201705628 B ZA201705628 B ZA 201705628B ZA 2017/05628 A ZA2017/05628 A ZA 2017/05628A ZA 201705628 A ZA201705628 A ZA 201705628A ZA 201705628 B ZA201705628 B ZA 201705628B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptides
- compositions
- methods
- eye diseases
- vectors
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8616—Special methods for targeting systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118934P | 2015-02-20 | 2015-02-20 | |
| PCT/US2016/018970 WO2016134375A1 (en) | 2015-02-20 | 2016-02-22 | Methods and compositions for treating genetic eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201705628B true ZA201705628B (en) | 2024-08-28 |
Family
ID=56689466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/05628A ZA201705628B (en) | 2015-02-20 | 2017-08-18 | Methods and compositions for treating genetic eye diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10472650B2 (https=) |
| EP (1) | EP3261440B1 (https=) |
| JP (1) | JP6873907B2 (https=) |
| KR (1) | KR102655319B1 (https=) |
| CN (1) | CN108347932B (https=) |
| AU (1) | AU2016219789B2 (https=) |
| CA (1) | CA2977355A1 (https=) |
| ES (1) | ES2920850T3 (https=) |
| SA (1) | SA517382162B1 (https=) |
| SG (1) | SG11201706755SA (https=) |
| WO (1) | WO2016134375A1 (https=) |
| ZA (1) | ZA201705628B (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3003391B1 (en) | 2013-05-31 | 2021-09-22 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| JP7610923B2 (ja) * | 2016-09-02 | 2025-01-09 | スパーク セラピューティクス インコーポレイテッド | Ｃｎｓ障害を治療するための方法及びベクター |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP2020534788A (ja) | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルスカプシド変異体及びその使用方法 |
| US12043848B2 (en) | 2017-10-16 | 2024-07-23 | Vigeneron Gmbh | AAV vectors |
| MX2020004643A (es) * | 2017-11-13 | 2021-01-29 | Univ California | Composiciones y metodos para mejorar la funcion visual. |
| CA3082450A1 (en) | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| SG11202009854XA (en) * | 2018-02-15 | 2020-11-27 | Bjoerklund Tomas | Modified viral capsids |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| AU2019227910B2 (en) * | 2018-02-28 | 2025-07-17 | The Regents Of The University Of California | A modular system for gene and protein delivery based on AAV |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| CN112770812A (zh) | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| SG11202107645RA (en) | 2019-01-18 | 2021-08-30 | Voyager Therapeutics Inc | Methods and systems for producing aav particles |
| WO2020206098A1 (en) * | 2019-04-03 | 2020-10-08 | Regenxbio Inc. | Gene therapy for eye pathologies |
| JP2022527116A (ja) * | 2019-04-08 | 2022-05-30 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Ｔｐｐ１を発現するａａｖの投与による眼のリソソーム蓄積症の治療 |
| EP3962536A1 (en) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| CN114729009A (zh) * | 2019-10-31 | 2022-07-08 | 伯尔尼大学 | 用于眼部基因递送的aav载体变体 |
| CN113025618B (zh) * | 2019-12-24 | 2024-02-06 | 朗信启昇(苏州)生物制药有限公司 | 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用 |
| US20230277685A1 (en) * | 2020-04-08 | 2023-09-07 | President And Fellows Of Harvard College | TGFß THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES |
| TWI900553B (zh) | 2020-05-13 | 2025-10-11 | 美商航海家醫療公司 | Aav蛋白殼之趨性重定向 |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| BR112023001456A2 (pt) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN113121655B (zh) * | 2021-04-19 | 2021-11-19 | 上海信致医药科技有限公司 | 眼部和肌肉特异靶向型腺相关病毒载体及其应用 |
| AU2022266615A1 (en) * | 2021-04-27 | 2023-11-09 | The General Hospital Corporation | Aav capsids and uses thereof |
| EP4405373A4 (en) * | 2021-09-21 | 2026-02-11 | California Inst Of Techn | VIRAL COMPOUNDS TO TARGET THE NERVOUS SYSTEM AND THE LUNGS |
| TW202325850A (zh) | 2021-11-29 | 2023-07-01 | 大陸商上海瑞宏迪醫藥有限公司 | Aadc、gdnf多核苷酸及其用於治療帕金森病 |
| CN114195859B (zh) * | 2021-12-10 | 2022-11-18 | 和元生物技术（上海）股份有限公司 | 一种适用于特异感染u251细胞的腺相关病毒突变体 |
| AU2023220219A1 (en) * | 2022-02-17 | 2024-09-05 | Skyline Therapeutics Limited | Recombinant adeno-associated virus with modified aav capsid polypeptides |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| WO2024017387A1 (en) | 2022-07-22 | 2024-01-25 | Shanghai Vitalgen Biopharma Co., Ltd. | Novel aav capsids for targeting nervous system and uses thereof |
| US20260085328A1 (en) | 2022-09-08 | 2026-03-26 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024207061A1 (en) * | 2023-04-04 | 2024-10-10 | Children's Medical Research Institute | Aav capsids and vectors for transduction of cells of the peripheral nervous system |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025214404A1 (en) | 2024-04-10 | 2025-10-16 | Skyline Therapeutics (Shanghai) Co., Ltd. | Optogenetic modulation for vision restoration |
| WO2025214408A1 (en) | 2024-04-10 | 2025-10-16 | Skyline Therapeutics (Shanghai) Co., Ltd. | Optogenetic modulation for vision restoration |
| KR102901502B1 (ko) * | 2024-06-27 | 2025-12-18 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
| WO2026005189A1 (ko) * | 2024-06-27 | 2026-01-02 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
| CN119039401B (zh) * | 2024-08-19 | 2025-04-11 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329501B1 (en) * | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| US6399575B1 (en) * | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| WO2002053703A2 (en) * | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| WO2009108274A2 (en) * | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| KR101154374B1 (ko) * | 2009-02-18 | 2012-07-09 | 재단법인 아산사회복지재단 | 표적화된 유전자 전달을 위한 아데노-부속 바이러스 혈청형5 벡터를 포함하는 조성물 |
| US20110052666A1 (en) * | 2009-09-03 | 2011-03-03 | Medtronic, Inc. | Compositions, Methods, and Systems for SIRNA Delivery |
| CN105755044A (zh) * | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| WO2013159036A1 (en) * | 2012-04-19 | 2013-10-24 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
-
2016
- 2016-02-22 AU AU2016219789A patent/AU2016219789B2/en active Active
- 2016-02-22 CA CA2977355A patent/CA2977355A1/en active Pending
- 2016-02-22 EP EP16753229.0A patent/EP3261440B1/en active Active
- 2016-02-22 CN CN201680022560.4A patent/CN108347932B/zh active Active
- 2016-02-22 WO PCT/US2016/018970 patent/WO2016134375A1/en not_active Ceased
- 2016-02-22 KR KR1020177026037A patent/KR102655319B1/ko active Active
- 2016-02-22 ES ES16753229T patent/ES2920850T3/es active Active
- 2016-02-22 SG SG11201706755SA patent/SG11201706755SA/en unknown
- 2016-02-22 JP JP2017543944A patent/JP6873907B2/ja active Active
- 2016-02-22 US US15/551,869 patent/US10472650B2/en active Active
-
2017
- 2017-08-18 ZA ZA2017/05628A patent/ZA201705628B/en unknown
- 2017-08-20 SA SA517382162A patent/SA517382162B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3261440A4 (en) | 2018-10-31 |
| AU2016219789B2 (en) | 2021-03-25 |
| NZ735344A (en) | 2024-09-27 |
| CN108347932A (zh) | 2018-07-31 |
| JP2018506980A (ja) | 2018-03-15 |
| KR102655319B1 (ko) | 2024-04-04 |
| SG11201706755SA (en) | 2017-09-28 |
| CA2977355A1 (en) | 2016-08-25 |
| KR20180012734A (ko) | 2018-02-06 |
| EP3261440B1 (en) | 2022-04-06 |
| US10472650B2 (en) | 2019-11-12 |
| WO2016134375A1 (en) | 2016-08-25 |
| AU2016219789A1 (en) | 2017-09-28 |
| BR112017017867A2 (pt) | 2018-04-10 |
| CN108347932B (zh) | 2022-09-13 |
| US20180142259A1 (en) | 2018-05-24 |
| JP6873907B2 (ja) | 2021-05-19 |
| EP3261440A1 (en) | 2018-01-03 |
| SA517382162B1 (ar) | 2021-11-02 |
| ES2920850T3 (es) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| EA202090817A1 (ru) | Триспецифические белки и способы их применения | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| EA201891092A1 (ru) | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках | |
| MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
| EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| MX2022015604A (es) | Expresion transgenica selectiva de tejidos. | |
| MX2022015079A (es) | Variantes de hsd17b13 y usos de las mismas. | |
| WO2017044857A3 (en) | Methods and compositions for the treatment of glaucoma | |
| EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
| MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
| MX2017011255A (es) | Sistema de vector múltiple y sus usos. | |
| MX2018005286A (es) | Constructo genetico. | |
| EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
| PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
| BR112019000171A2 (pt) | métodos e composições para tratamento de distúrbios e doenças envolvendo rdh12 | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| SA521422323B1 (ar) | Ii معززات هجين واستخداماتها في العلاج، ولا سيما في علاج الأمراض المرتبطة بالكولاجين من النوع | |
| JOP20200253A1 (ar) | تركيبات وطرق لعلاج الحثل البقعي | |
| WO2016205397A3 (en) | Target-specific delivery of therapeutic agents | |
| WO2019046341A3 (en) | Methods and compositions for treating cone-rod retinal dystrophy | |
| EA201991181A1 (ru) | Psma-нацеленные триспецифические белки и способы их применения | |
| EA201992692A1 (ru) | Нацеленные на msln триспецифические белки и способы применения |